Corporate | 28 October 2009 07:30
STRATEC Biomedical Systems AG / Quarter Results/Interim Report 28.10.2009 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STRATEC on growth course - Sales of Euro 19.4 million in Q3/2009 (+32.1%) - EBIT margin developing on target (Q3/2009: 18.1%, Q1-Q3/2009: 17.5%) - Sales boosted to Euro 56.0 million in Q1-Q3/2009 (+26.5%) - Consolidated net income of Euro 7.8 million in first nine months (+36.6%) - Delivery of pre-serial systems in Q3/2009 Birkenfeld, October 28, 2009 STRATEC Biomedical Systems AG today released its figures for the period January 1, 2009 to September 30, 2009 upon publication of its interim report as of September 30, 2009.Key Figures (EUR 000s) 01/01/-09/30/2009 01/01/-09/30/2008 Change Sales 56,001 44,256 + 26.5% Overall performance 62,164 48,595 + 27.9% EBITDA 11,735 8,964 + 30.9% EBIT 9,775 7,240 + 35.0% Consolidated net income 7,788 5,701 + 36.6% Earnings per share (EUR) 0.69 0.50 + 38.0% EBIT margin (%) 17.5 16.4Financial performance - The positive development in the company's operating business is reflected in its sales and earnings figures for the first nine months of the current financial year and has mainly been driven by strong demand for existing analyzer systems, as well as for consumables such as maintenance kits. Moreover, a number of pre-serial systems have also been supplied in recent months. Serial production of these systems is currently being launched. Against this backdrop, the company further boosted its sales by 32.1% to Euro 19.4 million in the period from July 1, 2009 to September 30, 2009 (Q3/2008: Euro 14.7 million) and generated EBIT of Euro 3.5 million over the same period (Q3/2008: Euro 2.4 million), equivalent to growth of 45.8%. The EBIT margin for the third quarter of 2009 amounted to 18.1% (Q3/2008: 16.4%). Sales for the first nine months of 2009 rose by 26.5% to Euro 56.0 million (Q1-Q3/2008: Euro 44.3 million) and are thus already at the upper end of our forecast range, which provides for sales growth of 20% to 30% in the 2009 financial year. EBIT was increased by 35.0% to Euro 9.8 million (Q1-Q3/2008: Euro 7.2 million). At 17.5% (Q1-Q3/2008: 16.4%), the EBIT margin for the first nine months of 2009 developed on schedule to reach the forecast range of 18.5% to 19.5% for the 2009 financial year as a whole. Project development - Our new developments have shown positive progress. For the first time in STRATEC's history, four development projects are simultaneously in the ramp-up phase for serial production. These newly developed analyzer systems will be launched by our customers in their respective market segments in the coming months. To account for these serial launches and for our development pipeline, which remains full, production capacities in Switzerland are currently being extended with a new building. The company's main location in Birkenfeld in Germany is due to be expanded in 2010. The construction projects will be financed by the cash flow from operations. These measures will only burden the company's stock of financial funds and depreciation rate to a minor extent. By extending its production sites, STRATEC will gain sufficient capacity to do justice to growing demand at our partners. Personnel development - Given the substantial expansion in our development divisions and preparations for the serial production of four analyzer system families, the total workforce of the STRATEC Group rose to 351 employees as of September 30, 2009 (09.30.2008: 274). The workforce has thus grown by 25 employees compared with June 30, 2009. Outlook - Our assessment in respect of the aforementioned growth rates for 2009 has been backed up by our positive current business performance. Our development and production capacities are very well utilized. The volume of production orders on hand gives grounds to expect further substantial growth in the fourth quarter of 2009. Furthermore, our planning indicators point to a continuing positive business performance in the 2010 and 2011 financial years as well. Furthermore, we are holding talks on promising projects with existing and potential customers. These lead us to expect further growth driven by new projects well beyond 2012. Further details can be found in our interim report as of September 30, 2009, which has been published under www.stratec-biomedical.de > IR News > Financial Reports. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Phone: +49 7082 7916 190 Fax: +49 7082 7916 999 Email: ir@stratec-biomedical.de 28.10.2009 Financial News transmitted by DGAP --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de Internet: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in München, Düsseldorf, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------